Reuters UK Business

Exclusive-Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say

By Foo Yun Chee BRUSSELS (Reuters) -Teva, the world’s largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday. The European Commission in 2022 charged the Israeli company …

Exclusive-Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say Read More »

REA Group makes initial takeover offer for UK property giant Rightmove, Bloomberg News reports

(Reuters) – Rupert Murdoch-owned property listings firm REA Group has made an initial takeover offer for Britain’s Rightmove, Bloomberg News reported on Tuesday citing people familiar with the matter. News Corp-backed REA Group had last week announced its interest in buying Rightmove to create a global real estate company. The current market capitalization of Rightmove …

REA Group makes initial takeover offer for UK property giant Rightmove, Bloomberg News reports Read More »

Weight-loss market to see 16 new drugs by 2029, report estimates

(Reuters) – The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk and Eli Lilly, according to estimates from analysts at Morningstar and Pitchbook. In a joint report published on Monday, analysts estimated the market for obesity treatments could expand …

Weight-loss market to see 16 new drugs by 2029, report estimates Read More »

Investors press Baloise to shake up business after Cevian swoop

By Oliver Hirt and Paul Arnold ZURICH (Reuters) – Swiss insurer Baloise is under pressure to heed shareholder demands to shake up its portfolio and boost returns since activist investor Cevian Capital said it held over 9% of the company’s stock, becoming its biggest stakeholder. Over the past decade, returns on Baloise’s shares, including dividends, …

Investors press Baloise to shake up business after Cevian swoop Read More »

Serica CEO says assets cash generative despite planned UK tax hike

By Arunima Kumar (Reuters) -Serica Energy’s new CEO said on Tuesday that its oil and gas producing assets remain cash generative, despite what he called “unjustifiably punitive” British taxes. Britain’s new Labour government said last month it would raise the Energy Profits Levy (EPL) imposed in 2022, by 3% to 38% from Nov. 1, bringing …

Serica CEO says assets cash generative despite planned UK tax hike Read More »

Fifth of industrial value creation in Germany under threat, BDI says

By Maria Martinez BERLIN (Reuters) – Around 20% of industrial value creation in Germany is under threat, according to a study published by the business association BDI on Tuesday. Germany is under more pressure as a business location than ever before in what should be a wake-up call for urgent reforms and investments, BDI said. …

Fifth of industrial value creation in Germany under threat, BDI says Read More »

Hearing aid makers slip after Apple rolls out hearing aid features, analysts shrug off threat

(Reuters) – Shares in European hearing aid makers slipped in early trading on Tuesday after Apple rolled out hearing aid features. Apple said its AirPods Pro 2 could now be “transformed” into a personalized hearing aid via an upcoming software update that would boost specific sounds in real time, including parts of speech or elements …

Hearing aid makers slip after Apple rolls out hearing aid features, analysts shrug off threat Read More »

AstraZeneca stock drops after lung cancer drug trial setback

(Reuters) -London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company’s lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients. The stock fell as much as 5.6% to 119.98 pounds in morning trade, with shares, which have gained nearly 18% this year, …

AstraZeneca stock drops after lung cancer drug trial setback Read More »

Exclusive-Boeing delays suppliers’ 737 MAX output goal by 6 months, sources say

By Allison Lampert (Reuters) -Boeing has told suppliers it is delaying a key production milestone for its 737 MAX by six months, three industry sources said, in a sign the planemaker is struggling to boost production of its best-selling jet. Boeing’s latest 737 supplier master schedule communicated to the industry calls for MAX output to …

Exclusive-Boeing delays suppliers’ 737 MAX output goal by 6 months, sources say Read More »

Close Bitnami banner
Bitnami